Log In
Print this Print this

dinutuximab (Unituxin) (formerly Ch14.18)

  Manage Alerts
Collapse Summary General Information
Company United Therapeutics Corp.
DescriptionChimeric mAb targeting ganglioside GD2 (GD2)
Molecular Target Ganglioside GD2 (GD2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentMarketed
Standard IndicationNeuroendocrine tumors
Indication DetailsTreat neuroblastoma; Treat pediatric neuroblastoma
Regulatory Designation U.S. - Orphan Drug (Treat neuroblastoma);
U.S. - Rare Pediatric Disease (Treat pediatric neuroblastoma);
U.S. - Standard Review (Treat neuroblastoma);
EU - Orphan Drug (Treat neuroblastoma);
EU - Standard Review (Treat neuroblastoma)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today